Targeted Combination Therapy
European Patent
18783979.0
Filed on 2018-04-11
18783979.0
Filed on 2018-04-11
Targeted Combination Therapy
China
201880038534.X
Filed on 2018-04-11
201880038534.X
Filed on 2018-04-11
Targeted Combination Therapy
Canada
3059882
Filed on 2018-04-11
3059882
Filed on 2018-04-11
Targeted Combination Therapy
Brazil
BR112019021476-3
Filed on 2018-04-11
BR112019021476-3
Filed on 2018-04-11
Targeted Combination Therapy
Australia
2018251788
Filed on 2018-04-11
2018251788
Filed on 2018-04-11
RAB13 AND NET1 ANTISENSE OLIGONUCLEOTIDES TO TREAT METASTATIC CANCER
US Patent 12,503,695
Filed on 2022-07-13
Filed on 2022-07-13
HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION
US Application 17/802,464
Filed on 2022-08-25
Filed on 2022-08-25
HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION
United Kingdom
2212195.8
Filed on 2022-08-22
2212195.8
Filed on 2022-08-22
HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION
Singapore
11202252357K
Filed on 2022-08-19
11202252357K
Filed on 2022-08-19
HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION
South Korea
10-2022-7033222
Filed on 2022-09-23
10-2022-7033222
Filed on 2022-09-23